C. diff. Spores and More

This episode introduces XBiotech, developer of True Human(TM) therapeutic antibodies. XBiotech has an exciting pipeline of product candidates in various areas of medicine. The Company recently announced the launch of a research and development program to develop a first-in-class oral monoclonal antibody against Clostridium difficile (C.difficile) infection. The Company will discuss the need for an effective C.difficile therapy, their novel approach to treating the disease as well as efficiency in their manufacturing technology. Join guests: Dr. Michael Stecher, Medical Director, Dr. Sushma Shivaswamy, Vice President of Research and Development, and Kelly Thornburg, Senior Vice President of Operations, as they discuss how XBiotech is pioneering a new era in the discovery and development of targeted antibodies therapeutics.

Listen in as our guest Shelby Lassiter, BSN,RN,CPHQ,CIC, Infection Preventionist, joins us to discuss the many ways on how to maintain infection control in a home environment while treating a C. diff. infection. That means how to eliminate the C. diff. spores and more!

This episode of “C. diff. Spores and More” is focused on “C. difficile Infections; The What, Where and How.” What is it, What can be done to prevent acquiring it, Where is it acquired, Where can clinicians and patients learn more about this infection, How is it being prevented at home and in the hospitals, How CDI’s are being treated, and How to learn more about the

prevention, treatments, and environmental safety products available With our special guests: Dr. Caterina Oneto,, MD and Dr. Paul Feuerstadt, MD, Both professors and physicians specializing in Gastroenterology with a wealth of knowledge and experience treating patients diagnosed with a CDI and through ongoing scientific/medical research.

Listen in as our guest Shelby Lassiter, BSN,RN,CPHQ,CIC, Infection Preventionist, joins us to discuss the many ways on how to maintain infection control in a home environment while treating a C. diff. infection. That means how to eliminate the C. diff. spores and more!

Join us to hear from Merck's Dr. Nick Kartsonis, and the history in addressing infectious disease and antimicrobial resistance. Dr. Nick Kartsonis will also be discussing the future in the area of C. diff. and some of the company's current treatments, including DIFICID and their ongoing research addressing CDI.

According to the Centers for Disease Control and Prevention (CDC) report published in

February 2015, almost 500,000 C.diff. infections occurred in the U.S. in 2011, with 83,000 recurrences. Join our guests, C. diff. survivors, Heather Clark, Veronica Edmond, Renetta Dudzinski, and Lisa Hurka-Covington as they bravely share their story and unique journey through a C. diff. infection that forever changed their lives.

Join us and learn from our guests;

Dr. Clifford McDonald, MD, Senior Advisor for Science and Integrity, Division of Healthcare Quality Promotion at the CDC with main interests in epidemiology and prevention of Healthcare-Associated Infections, especially Clostridium difficile infections, and the prevention of antimicrobial resistance. And

Dr. Arjun Srinivasan, MD, Associate Director for Healthcare-Associated Infection prevention programs in the Division of Healthcare Quality Promotion at CDC's National Center for Emerging and Zoonotic Infectious Disease. Listen in as these two stellar Physicians discuss the topics of Clostridium difficile infections and Antibiotic usage, two important issues with potential solutions facing the citizens on a global level..

Join us and our three guests,

Bradley Whitchurch, Founder and Chairman of the Board at Seal Shield, LLC,

Dr. Rosie D. Lyles, MD, Clinical Affairs Head, Research and Department, Clorox Healthcare and

Shelby Lassiter, BSN, RN, CPHQ, CIC, an Infection Preventionist as they come together to discuss

C. diff. infections, hospital-associated infections,

and you will want to know why hand hygiene

alone is not enough, plus infection prevention

measures in the healthcare and home settings.

Dr. Mark Stibich, PhD, Chief Scientific Officer & Co-founder, Xenex. and Ms. Sarah Simmons, MPH CIC, Science Director, Xenex discuss pulsed xenon UV light room disinfection technology. Dr. Stibich and

Ms. Simmons will share information how pulsed UV disinfection works, the pulsed Xenon UV (PX-UV) difference, and the effectiveness against endospores like C. diff. and bacillus strains and more.